20/20 Biolabs, Inc. Common Stock (AIDX) - Total Liabilities
Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has total liabilities worth $3.13 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AIDX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
20/20 Biolabs, Inc. Common Stock - Total Liabilities Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of 20/20 Biolabs, Inc. Common Stock.
20/20 Biolabs, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xenetic Biosciences Inc
NASDAQ:XBIO
|
USA | $1.11 Million |
|
ESE Entertainment Inc
V:ESE
|
Canada | CA$9.18 Million |
|
Manugraph India Limited
NSE:MANUGRAPH
|
India | Rs-580.38 Million |
|
Australasian Metals Ltd
AU:A8G
|
Australia | AU$210.16K |
|
Bri-Chem Corp.
TO:BRY
|
Canada | CA$20.68 Million |
|
Datametrex AI Ltd
V:DM
|
Canada | CA$5.55 Million |
|
Novakand Pharma AB (publ)
ST:LARK
|
USA | Skr846.00K |
|
Corus Entertainment Inc
TO:CJR-B
|
Canada | CA$2.04 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down 20/20 Biolabs, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AIDX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 28.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 20/20 Biolabs, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual total liabilities of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.08 Million | -0.07% |
| 2023-12-31 | $2.08 Million | -26.77% |
| 2022-12-31 | $2.84 Million | -16.02% |
| 2021-12-31 | $3.38 Million | +162.58% |
| 2020-12-31 | $1.29 Million | +31.91% |
| 2019-12-31 | $976.56K | +19.01% |
| 2018-12-31 | $820.54K | -15.05% |
| 2017-12-31 | $965.94K | +71.89% |
| 2016-12-31 | $561.95K | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more